AG-181 — Initial data
H2 2026
Data from this trial are expected in the second half of 2026.Source filing
AGIO biotech catalysts & pipeline
AGIOS PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
tebapivat — Topline data
H2 2026
Agios expects to report topline results from its Phase 2 trial in the second half of 2026.Source filing
PYRUKYND (mitapivat) — PDUFA
Nov 1
The Prescription Drug User Fee Act (PDUFA) goal date for this sNDA, submitted under the FDA's accelerated approval pathway, is November 1, 2026.Source filing